Skip to content

Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

Research output: Contribution to journalArticle

  • John M Gregson
  • Daniel F Freitag
  • Praveen Surendran
  • Nathan O Stitziel
  • Rajiv Chowdhury
  • Stephen Burgess
  • Kaptoge Stephen
  • Pei Gao
  • James R Staley
  • Peter Willeit
  • Sune F Nielsen
  • Muriel Caslake
  • Stella Trompet
  • Linda M Polfus
  • Kari Kuulasmaa
  • Jukka Kontto
  • Markus Perola
  • Stefan Blankenberg
  • Giovanni Veronesi
  • Francesco Gianfagna
  • Satu Mannisto
  • Akinori Kimura
  • Honghuang Lin
  • Dermot F Reilly
  • Mathias Gorski
  • Vladan Mijatovic
  • CKDGen consortium
  • Patricia B Munroe
  • Georg B Ehret
  • International Consortium for Blood Pressure
  • Alex Thompson
  • Maria Uria-Nickelsen
  • Anders Malarstig
  • Abbas Dehghan
  • CHARGE inflammation working group
  • Thomas F Vogt
  • Taishi Sasaoka
  • Fumihiko Takeuchi
  • Norihiro Kato
  • Yoshiji Yamada
  • Frank Kee
  • Martina Muller-Nurasyid
  • Jean Ferrieres
  • Dominique Arveiler
  • Philippe Amouyel
  • Veikko Salomaa
  • Eric Boerwinkle
  • Simon G Thompson
  • Ian Ford
  • J Wouter Jukema
  • Naveed Sattar
  • Chris J Packard
  • Abdulla al Shafi Majumder
  • Dewan S Alam
  • Panos Deloukas
  • Heribert Schunkert
  • Nilesh J Samani
  • Sekar Kathiresan
  • MICAD Exome consortium
  • Borge G Nordestgaard
  • Danish Saleheen
  • Joanna M M Howson
  • Emanuele Di Angelantonio
  • Adam S Butterworth
  • John Danesh
  • EPIC-CVD consortium
  • CHD Exome+ consortium
Original languageEnglish
Pages (from-to)492-504
Number of pages13
JournalEuropean Journal of Preventive Cardiology
Volume24
Issue number5
Early online date8 Dec 2016
DOIs
DateAccepted/In press - 24 Oct 2016
DateE-pub ahead of print - 8 Dec 2016
DatePublished (current) - 3 Mar 2017

Abstract

Aims Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), has not reduced risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA2 enzyme activity is causally relevant to coronary heart disease. Methods In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional variants: four rare loss-of-function mutations (c.109+2T > C (rs142974898), Arg82His (rs144983904), Val279Phe (rs76863441), Gln287Ter (rs140020965)) and one common modest-impact variant (Val379Ala (rs1051931)) in PLA2G7, the gene encoding Lp-PLA2. We supplemented de-novo genotyping with information on a further 45,823 coronary heart disease patients and 88,680 controls in publicly available databases and other previous studies. We conducted a systematic review of randomized trials to compare effects of darapladib treatment on soluble Lp-PLA2 activity, conventional cardiovascular risk factors, and coronary heart disease risk with corresponding effects of Lp-PLA2-lowering alleles. Results Lp-PLA2 activity was decreased by 64% (p = 2.4 × 10–25) with carriage of any of the four loss-of-function variants, by 45% (p < 10–300) for every allele inherited at Val279Phe, and by 2.7% (p = 1.9 × 10–12) for every allele inherited at Val379Ala. Darapladib 160 mg once-daily reduced Lp-PLA2 activity by 65% (p < 10–300). Causal risk ratios for coronary heart disease per 65% lower Lp-PLA2 activity were: 0.95 (0.88–1.03) with Val279Phe; 0.92 (0.74–1.16) with carriage of any loss-of-function variant; 1.01 (0.68–1.51) with Val379Ala; and 0.95 (0.89–1.02) with darapladib treatment. Conclusions In a large-scale human genetic study, none of a series of Lp-PLA2-lowering alleles was related to coronary heart disease risk, suggesting that Lp-PLA2 is unlikely to be a causal risk factor.

Download statistics

No data available

Documents

Documents

  • Supplementary information PDF

    Accepted author manuscript, 871 KB, PDF document

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Sage at http://journals.sagepub.com/doi/10.1177/2047487316682186. Please refer to any applicable terms of use of the publisher.

    Final published version, 285 KB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups